You are here

Guillaume Poncet-Montange


Palmer WS, Poncet-Montange G, Liu G et al. Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor. J Med Chem. 2016; 59(4); 1440-54.

Poncet-Montange G, Zhan Y, Bardenhagen JP et al. Observed bromodomain flexibility reveals histone peptide- and small molecule ligand-compatible forms of ATAD2. Biochem J. 2015;466(2):337–346.

Gelin M, Poncet-Montange G, Assairi L, et al. Screening and in situ synthesis using crystals of a NAD kinase lead to a potent antistaphylococcal compound. Structure. 2012;20(6):1107–1117.

Poncet-Montange G, St Martin SJ, Bogatova OV, et al. A survey of antiprion compounds reveals the prevalence of non-PrP molecular targets. J Biol Chem. 2011 Aug 5;286(31);27718–27728.

Guillaume Poncet-Montange, Pharm.D., Ph.D.

Guillaume Poncet-Montange is a senior group leader in the Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard. He leads the structural biology group and a multi-disciplinary therapeutic project involving 50 scientists through a collaboration with Calico and AbbVie. Poncet-Montange is a pharmaceutical scientist with a passion for drug discovery, and he worked in numerous therapeutic areas including neurodegenerative diseases, oncology (epigenetics), and infectious diseases.

Prior to joining the Broad Institute in 2018, Poncet-Montange used his background in pharmaceutical research and structural biology to develop a consistent track record of collaborations and scientific discoveries at a start-up company, Orthogon Therapeutics, LLC, and at the MD Anderson Cancer Center Institute for Applied Cancer Science.A noteworthy achievement includes Poncet-Montange’s contribution to develop IACS-9571, the first-in-class inhibitor of TRIM24. He has been awarded patents with the Pasteur Institute.

Poncet-Montange’s core interests include structure-function of therapeutic targets and structure-based drug design, leveraging x-ray crystallography, cryo-EM, cheminformatics, bioinformatics, biophysics, biochemistry, and innovative drug discovery technologies.

Poncet-Montange holds a Pharm.D. from Université Paul Sabatier Toulouse III and a Ph.D. in structural biology from the University of Montpellier 1. His postdoctoral research was undertaken first at the University of Montpellier 2 and subsequently at the University of California, San Francisco in the lab of Nobel Laureate Stanley Prusiner.

Contact Guillaume Poncet-Montange via email at

July 2022